Brazil faces a boom in the black market for weight-loss drugs amid GLP-1 demand
The high cost of GLP-1 treatments and prescription restrictions are driving illegal sales in Brazil of tirzepatide from Paraguay and unregulated compounded preparations. Itaú BBA estimates off-pharmacy sales will reach nearly 19 billion reais this year, of which about 6.5 billion would come from Paraguayan products diverted into the country. Anvisa and the Federal Police are investigating the health risks, while pharmacy robberies targeting these drugs worry authorities.
In 40 seconds
- Itaú BBA estimates off-pharmacy GLP-1 sales of nearly 19 billion reais in Brazil this year, with about 6.5 billion coming from diverted Paraguayan products.
- Paraguayan tirzepatide is obtained via WhatsApp and social media and delivered by courier, without Anvisa registration.
- In July authorities seized nearly 6,000 pens and vials at the Friendship Bridge, the largest seizure ever recorded there.
IASummary generated by artificial intelligence from a story by Bloomberg Línea. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.